Personalised SGLT2i treatment in diabetic kidney disease supported by multiparametric renal magnetic resonance imaging

Promoting personalized medicine

Uncovering early mechanisms and predictors of how patients with diabetic kidney disease respond to SGLT2 inhibitors, using advanced MRI and molecular biomarkers

Focuses on creating a sustainable ecosystem

Aiming to refine and validate these biomarkers to enable personalised treatment, better monitoring of disease progression, and more effective patient care.

Latest news

View all news

What do they say?

Investigating SGLT2 inhibitors' nephroprotective mechanisms in DKD is critical to identify individuals most likely to benefit from these drugs, and thus foster personalised treatment
Anna Caroli
Anna CaroliCoordinator
Application of renal multiparametric MRI techniques will allow us to evaluate the impact of SGLT2 inhibition on renal microstructure and function
Maria A. Fernández Seara
Maria A. Fernández SearaProject partner 1
We will identify, in preclinical settings, the renal mpMRI biomarkers that are most sensitive to both the acute and chronic effects of SGLT2 inhibitors in DKD.
Christoffer Lautsen
Christoffer LautsenProject partner 2
We will determine the most informative combinations of biomarkers and capable of monitoring DKD progression and therapeutic response to SGLT2 inhibitors
Frank Zöllner
Frank ZöllnerProject partner 3
I believe that trustworthy and harmonised AI-driven analysis of renal MRI is essential to support multicentre research and enable personalised management of chronic kidney disease.
Lucian-Mihai Itu
Lucian-Mihai ItuProject partner 4
As personalised treatment approaches reshape the future of DKD care, it is essential to address the emerging ethical and social issues with transparency and by actively involving patients, clinicians, and wider communities in the process”
Signe Mezinska
Signe MezinskaProject partner 5
New treatment options offer a renewed perspective for people diagnosed with CKD, particularly those whose underlying condition is type 2 diabetes. The ability to tailor treatments to the real needs of each individual patient represents a fascinating challenge.
Juan Carlos Julián Mauro
Juan Carlos Julián MauroProject partner 6
heildelberg
aarhus
cun
siemens
irmfn
2024_LU_logotips_ENG_horiz.jpg
Logo EKPF

Leave a message